EGFR-MUTATED NSCLC
Clinical trials for EGFR-MUTATED NSCLC explained in plain language.
Never miss a new study
Get alerted when new EGFR-MUTATED NSCLC trials appear
Sign up with your email to follow new studies for EGFR-MUTATED NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough lung cancer mutation
Disease control Recruiting nowThis early-stage trial tests a new oral drug called ORIC-114 combined with an injectable drug, amivantamab, in people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The study aims to find the safest dose and see if the combination shrinks tu…
Matched conditions: EGFR-MUTATED NSCLC
Phase: PHASE1 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Lung cancer relapse mystery: new study digs into genetic clues
Knowledge-focused Recruiting nowThis study looks at 100 people with a specific type of lung cancer (EGFR-mutated NSCLC) whose cancer came back during or after treatment with the drug osimertinib. Researchers want to find out what new genetic changes appear when the cancer returns. This is an observational study…
Matched conditions: EGFR-MUTATED NSCLC
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC